Hints and tips:
...The FTSE 100 company – whose interests range from tools for sports medicine and high-tech woundcare products to artificial hips and knees – reported sales of $1.1bn in the final three months of the year,...
...The $782m all-cash deal will give the FTSE 100 medical device maker a foothold in the $1bn-a-year market for bioactive wound care, where treatments derived from proteins or cells are used to accelerate healing...
International Edition